Here are the 10-K annual reports from Enveric Biosciences, Inc. (ENVB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ENVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENVB filings page.
Enveric Biosciences is a Delaware-based biotechnology company developing next‑generation, non‑hallucinogenic neuroplastogenic drugs for psychiatric and neurological disorders. Its lead candidate, EB‑003, a DMT‑derived compound from the EVM301 Series, is in preclinical development with IND‑enabling studies planned.
The company also maintains a large psychedelic‑inspired IP library (Psybrary™) and has out‑licensed certain cannabinoid and psychedelic assets. As of June 30, 2025, non‑affiliate equity value was about $3.6 million, and the auditor has raised substantial doubt about Enveric’s ability to continue as a going concern due to recurring losses and funding needs.